1 Information professionnelle suisse Lithiofor®. Disponible sur:
www.swissmedicinfo.ch, dernier accès le 17/10/2017.
2 Bauer M, G.M., The essential guide to lithium treatment, Springer, Editor. 2016.
3 Sproule BA, Hardy BG, Shulman KI. Differential pharmacokinetics of lithium in elderly patients. Drugs Aging. 2000;16(3):165–77.
4 Rej S, et al. Lithium dosing and serum concentrations across the age spectrum: from early adulthood to the tenth decade of life. Drugs Aging. 2014;31(12):911–6.
5 Slater V, et al. Influence of age on lithium therapy. South Med J. 1984;77(2):153–4,158.
6 Phelan K.M, A.D. Mosholder, and S. Lu, Lithium interaction with the cyclooxygenase 2 inhibitors rofecoxib and celecoxib and other nonsteroidal anti-inflammatory drugs. J Clin Psychiatry. 2003;64(11):1328–34.
7 Ratz Bravo A.E, et al. Lithium intoxication as a result of an interaction with rofecoxib. Ann Pharmacother.
2004;38(7–8):1189–93.
8 Noroian G. and D. Clive, Cyclo-oxygenase-2 inhibitors and the kidney: a case for caution. Drug Saf. 2002;25(3):165–72.
9 Ohman R. and O. Spigset, Serotonin syndrome induced by fluvoxamine-lithium interaction. Pharmacopsychiatry. 1993;26(6):263–4.
10 Noveske F.G, K.R. Hahn, and R.J. Flynn, Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry. 1989;146(11):1515.